These T-cell intrinsic defects may potentially explain the finding that meta-analysis of clinical trials shows lower rates of CD19-CART-mediated remissions in CLL compared to other hematologic malignancies (2, 182). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.